VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months
VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months
复制标题
DOI：
10.1093/ajcp/aqz153
复制
发表时间：
2020-02-01
影响因子：
3.5
通讯作者：
Linden, Michael A.
中科院分区：
文献类型：
--
作者：
Courville, Elizabeth L.;Yohe, Sophia;Linden, Michael A.
目的：我们报告了我们使用VS38流式细胞术评估浆细胞的机构经验。方法：重新分析流式细胞术数据，比较标准组和VS38组的浆细胞百分比。计算自然杀伤细胞（NK）和浆细胞CD38中位荧光强度（MFI）值。结果：我们的队列包括来自38例患者的63份标本。其中26人在1个月至17个月之前接受了达拉单抗（单克隆抗cd38治疗）。NK细胞和浆细胞CD38 MFI值被抑制0 ~ 4个月，最后一次暴露后4 ~ 6个月开始升高。VS38与标准板计算的克隆浆细胞百分比无显著差异；然而，使用VS38面板进行鉴定和定量更容易。结论：VS38是一种可行的替代亮CD38来识别浆细胞的方法，对暗CD38骨髓瘤病例和达拉单抗治疗后特别有用。达拉单抗对CD38识别的干扰在最后一次暴露后持续4至6个月。
Objectives: We report our institutional experience using VS38 to evaluate plasma cells by flow cytometry.Methods: Flow cytometry data were reanalyzed to compare plasma cell percentages between the standard panel and VS38 panel. Natural killer (NK) and plasma cell CD38 median fluorescence intensity (MFI) values were calculated.Results: Our cohort included 63 specimens from 38 patients. Twenty-six had received daratumumab (monoclonal anti-CD38 therapy) between less than 1 month and 17 months prior. For NK and plasma cells, CD38 MFI values were suppressed for 0 to 4 months and started to increase 4 to 6 months after last exposure. There was no significant difference in clonal plasma cell percentage calculated by the VS38 and standard panels; however, identification and quantification using the VS38 panel were easier.Conclusions: VS38 is a viable alternative to bright CD38 to identify plasma cells and particularly helpful in myeloma cases with dim CD38 and after daratumumab. Daratumumab interference with CD38 identification persists 4 to 6 months after the last exposure.